EC Number   |
Activating Compound |
Reference |
|---|
   3.4.24.86 | heparan sulfate |
removal of cell surface heparan sulfate increases TACE activity and TACE-dependent formation of ErbB4 80 kDa intracellular domain |
711594 |
| 3.4.24.86 | hydrogen peroxide |
- |
711689 |
| 3.4.24.86 | interleukin-4 |
granulocyte-macrophage colony-stimulating factor GM-CSF and interleukin-4 in combination potently up-regulate tumor necrosis factor-alpha coverting enzyme TACE and activity in monocytes, causing ectodomain shedding of M-CSF receptor |
711568 |
| 3.4.24.86 | lipopolysaccharide |
- |
638985, 638989, 639002 |
| 3.4.24.86 | lipopolysaccharide |
lipopolysaccharide-vehicle or lipopolysaccharide-ranitidine treatments of rats causes a significant increase in hepatic TACE activity |
699749 |
| 3.4.24.86 | more |
actin cytoskeletal disruption causes endogenous activation of TACE and accumulation at the plasma membrane |
735270 |
| 3.4.24.86 | more |
no apparent change in mRNA contents of TACE upon stimulation with IFN alpha, IFN beta and IFN gamma |
682211 |
| 3.4.24.86 | more |
no effect: removal of chondroitin sulfate |
711594 |
| 3.4.24.86 | more |
substrate glycosylation increases the enzyme activity, overview |
734195 |
| 3.4.24.86 | more |
TACE activation by stimulating epithelial growth factor receptor occurs via p38/ERK |
735270 |
